ARCT

#3092
Arcturus Therapeutics Holdings Inc. - Common Stock
7.9 3 USD
+0.13%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
7.87
7.96
Range Annuel
5.86
24.14
Changement quotidien
+0.13%
Changement Mensuel
-5.26%
Evolution sur 6 mois
+17.83%
Changement Annuel
-37.21%
Clôture Précédente
7.9 2
Open
7.9 0
Low
7.8 7
High
7.9 6
Volume
169
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 225.39 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-2.55
ratio cours/chiffre d'affaires
2.05

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Nouvelles